Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data for EDP-978, the Company’s KIT inhibitor in development for the treatment of mast cell-mediated, Type 2 immune diseases, will be presented in two poster presentations at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting being held February 27 – March 2, 2026 in Philadelphia, PA.

Details of the presentations are as follows:

Abstract Title: Discovery of a Potent and Selective KIT inhibitor for Treatment of Mast Cell-Mediated Diseases
Date: Friday, February 27, 2026
Time: 2:45 – 3:45 PM EST
Poster Number: 104
Session: Allergic Skin Diseases
Location: Convention Center, Level 2, Hall E
Presenter: Tessa Cressey, Ph.D.

Abstract Title: EDP-978, a Potent KIT Inhibitor, Demonstrated Dose-Dependent Target-Engagement and a Favorable Pharmacokinetic Profile with Once-Daily Dosing Potential in Humans
Date: Friday, February 27, 2026
Time: 2:45 – 3:45 PM EST
Poster Number: 038
Session: Allergic Skin Diseases
Location: Convention Center, Level 2, Hall E
Presenter: Yang Li, Ph.D.

Abstracts are available in an online supplement to The Journal of Allergy and Clinical Immunology (JACI) platform here . Further information about AAAAI 2026 can be found here . Posters will be available on Enanta’s website here after presentations are held on February 27, 2026.

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and immunological diseases. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, with KIT, STAT6 and MRGPRX2 inhibition.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET ^® (U.S.) and MAVIRET ^® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260210569136/en/